In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin
| Autor: | Jochen Wiesner, Dajana Henschker, David B. Hutchinson, Hassan Jomaa, Ewald Beck |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Plasmodium vinckei
medicine.drug_class Plasmodium falciparum Biology Pharmacology Antimalarials Mice Fosfomycin In vivo parasitic diseases medicine Animals Humans Experimental Therapeutics Pharmacology (medical) Lincosamides Dose-Response Relationship Drug Clindamycin Drug Synergism Drug interaction biology.organism_classification Fosmidomycin Anti-Bacterial Agents Malaria Lincomycin Infectious Diseases medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 46:2889-2894 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.46.9.2889-2894.2002 |
| Popis: | Fosmidomycin acts through inhibition of 1-deoxy- d -xylulose 5-phosphate (DOXP) reductoisomerase, a key enzyme of the nonmevalonate pathway of isoprenoid biosynthesis. It possesses potent antimalarial activity in vitro and in murine malaria. In a recent clinical study, fosmidomycin was effective and well tolerated in the treatment of patients with acute uncomplicated Plasmodium falciparum malaria but resulted in an unacceptably high rate of recrudescence. In order to identify a potential combination partner, the interaction of fosmidomycin with a number of antimalarial drugs in current use was investigated in a series of in vitro experiments. Synergy was observed between fosmidomycin and the lincosamides, lincomycin and clindamycin. The efficacy of a combination of fosmidomycin and clindamycin was subsequently demonstrated in the Plasmodium vinckei mouse model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|